MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
IDXX stock logo

IDXX

IDEXX Laboratories, Inc.

$569.55
4.89
 (0.87%)
Exchange:  NASDAQ
Market Cap:  45.35B
Shares Outstanding:  80M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Diagnostics & Research
   
CEO:  Jonathan J. Mazelsky
Full Time Employees:  11000
Address: 
One IDEXX Drive
Westbrook
ME
4092
US
Website:  https://www.idexx.com
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/05/01 — Q1 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue3,660,9533,897,5044,303,702
Gross Profit2,189,9702,378,9272,659,579
EBITDA1,217,6651,275,8401,468,916
Operating Income1,097,1281,128,3371,360,031
Net Income845,042887,8671,059,464

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets3,259,9253,293,4433,350,759
Total Liabilities1,775,3951,698,1301,745,376
Total Stockholders Equity1,484,5301,595,3131,605,383
Total Debt1,067,353986,94874,995
Cash and Cash Equivalents453,932288,266180,070

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow906,510929,0011,181,805
Capital Expenditure-133,631-120,922-124,676
Free Cash Flow772,879808,0791,057,129
Net Income845,042887,8671,059,464
Net Change in Cash341,386-165,666-108,196

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)6,944,443.252Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)7,071,016.370Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)6,998,000Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)2,258,279.120Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)2,299,439.717Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)2,275,695.360Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)2,093,454.156Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)2,143,172.545Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)2,114,491.776Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)1,742,715.333Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)1,774,478.990Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)1,756,155.455Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)26.210Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)26.570Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)25.950Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)4Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)6Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
3.898B  ?P/S
 (TTM)
: 
10.42
?Net Income
 (TTM)
: 
887.867M  ?P/E
 (TTM)
: 
42.56
?Enterprise Value
 (TTM)
: 
45.725B  ?EV/FCF
 (TTM)
: 
43.41
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
0.7  ?ROIC
 (TTM)
: 
0.4
?Net Debt
 (TTM)
: 
698.682M  ?Debt/Equity
 (TTM)
: 
0.67
?P/B
 (TTM)
: 
28.09  ?Current Ratio
 (TTM)
: 
1.17

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
39.42Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates IDXX intrinsic value between $143.16 – $446.80 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate IDXX Intrinsic Value

Common questions about IDXX valuation

Is IDEXX Laboratories, Inc. (IDXX) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for IDEXX Laboratories, Inc. (IDXX) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is IDXX a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether IDXX trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is IDXX’s P/E ratio?

You can see IDXX’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for IDXX?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is IDXX a good long-term investment?

Whether IDXX fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

IDXX

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

0.87
MARKETSnap

Trading Metrics:

Open: 557.73   Previous Close: 564.66
Day Low: 550   Day High: 575.43
Year Low: 356.14   Year High: 769.98
Price Avg 50: 621.84   Price Avg 200: 637.14
Volume: 693769   Average Volume: 520908

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Will Idexx (IDXX) Beat Estimates Again in Its Next Earnings Report?
13-04-2026 13:11
Will Idexx (IDXX) Beat Estimates Again in Its Next Earnings Report?
IDEXX Laboratories Stock Up 39.4% in a Year: What's Driving It?
13-04-2026 09:30
IDEXX Laboratories Stock Up 39.4% in a Year: What's Driving It?
IDEXX Laboratories to Release 2026 First Quarter Financial Results
08-04-2026 13:00
Idexx (IDXX) Upgraded to Buy: Here's Why
Why Idexx Laboratories (IDXX) is a Top Growth Stock for the Long-Term
IDEXX Announces UK Availability of Cancer Dx Panel for Early Detection of Canine Lymphoma

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read